Official Title
Expanded Access to Glecaprevir/ Pibrentasvir
Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Approved for marketing
Individual Patients
Hepatitis C Virus Infection

Drug: glecaprevir
Glecaprevir will be administered orally.
Other Name: ABT-493

Drug: pibrentasvir
Pibrentasvir will be administered orally.
Other Name: ABT-530

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Slovenia

AbbVie Inc.
Study Director
AbbVie

NCT Number
Keywords
Special Access Scheme
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
MeSH Terms
Hepatitis C